Related Experiment Video
Updated: Dec 25, 2025
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Regulatory Science, and How Device Regulation Will Shape Our Future
Nicole Ibrahim1,2, Nicole Gillette3, Hetal Patel3
1Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD, USA. Nicole.Ibrahim@fda.hhs.gov.
Insights
Pediatric medical device development faces regulatory hurdles. Innovations like early feasibility studies, 3D printing, and real-world evidence can accelerate pediatric device approvals.
Area of Science:
- Biomedical Engineering
- Regulatory Science
- Pediatric Cardiology
Background:
- Pediatric medical devices are often adapted from adult applications, leading to slower innovation.
- Regulatory processes are a key factor influencing the development and commercialization of pediatric devices.
- Existing challenges necessitate advancements to meet the unique needs of children.
Purpose of the Study:
- To highlight key regulatory areas that can advance pediatric cardiology device development.
- To identify innovations supporting pediatric device innovation from conception to commercialization.
- To emphasize the importance of regulatory pathways for pediatric medical devices.
Main Methods:
- Review of FDA's Center for Devices and Radiological Health (CDRH) initiatives.
- Analysis of four key regulatory areas: Early Feasibility Study Program, 3D printing, computational modeling, and real-world evidence.
- Discussion of the impact of these programs on the device development lifecycle.
Main Results:
- The CDRH Early Feasibility Study Program can facilitate early-stage device testing.
- Advancements in 3D printing offer new prototyping and customization possibilities.
- Computational modeling and simulation can aid in design and predict device performance.
- Real-world evidence provides valuable data for regulatory decision-making.
Conclusions:
- These regulatory and technological advancements have the potential to significantly improve pediatric device development.
- Collaboration among stakeholders is crucial for the successful implementation of these programs.
- Addressing regulatory aspects is fundamental to improving the availability of innovative medical devices for children.
Abstract:
Pediatric medical device approvals lag behind adult approvals. Historically, medical devices have rarely been designed specifically for children, but use in children has most often borrowed from adult or general use applications. While a variety of social, economic, and clinical factors have contributed to this phenomenon, the regulatory process remains a fundamental aspect of pediatric device development and commercialization. FDA's Center for Devices and Radiological Health (CDRH) has established programmatic and technological areas of advancement to support innovation that serves the public health needs of children and special populations. We highlight four regulatory areas that have the potential to shape the future of pediatric cardiology: the CDRH Early Feasibility Study Program, advancements in 3D printing or additive manufacturing, computational modeling and simulation, and the use of real-world evidence for regulatory applications. These programs have the potential to impact all stages of device development, from early conception, design, and prototyping to clinical evidence generation, regulatory review, and finally commercialization. The success of these programs relies on a collaborative community of stakeholders, including government, regulators, device manufacturers, patients, payers, and the academic and professional community societies.
Related Concept Videos
01:25Drug Regulation
01:03Drug Control Governance: Regulatory Bodies and Their Impact
01:28Global Regulatory Systems
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:28Drug Products: Biologics, Biosimilars and Interchangeables